Your Guide to Psychedelics

Gain access to the psychedelic industry’s most robust platform for free.

Join over 3,000 community members

Researchers

Founders

Investors

Therapists

Activists

Find the Psychedelic Courses That Can Launch Your Career

Therapists and sitters are needed to lead the growth of the psychedelic-assisted therapy that is slated to help millions.

Access and Inclusion in Psychedelic Treatment

Psychedelic-assisted therapy is making its way through the established medical system’s approval process and moving towards becoming an available treatment...

Psychedelics

Poetry, Symbols, and Story in Psychedelic Therapy

“And as imagination bodies forth the forms of things unknown, the poet’s pen turns them to shapes and gives to...

Psilocybin-Assisted Therapy: Part 2

In this course trainees receive instruction in psilocybin administration, integration, and group formats for psychedelic facilitation. Trainees are encouraged to...

Psilocybin

Community Psilocybin Harm Reduction Course

Community Psilocybin Harm Reduction Course. In this training course you will learn the benefits of harm reduction and how harm...

Psilocybin

Skylight Psychedelics Ketamine-Assisted Therapy Training + Psilocybin Training/Harm Reduction Course

Ketamine-Assisted Therapy Training PLUS Psilocybin-Assisted Therapy/Harm Reduction

Psilocybin Ketamine

Skylight Psychedelics Ketamine-Assisted Therapy Training Course

A comprehensive course for licensed therapists & providers.

Skylight Psychedelics Psilocybin-Assisted Therapy Training Course: The Comprehensive Harm Reduction Guide from the Underground

The Comprehensive Harm Reduction Guide from the Underground. This course is most comprehensive guide available of its kind. Designed by...

Microdosing

A proven science-based process to enhance emotional balance, holistic wellness, and peak performance. Unleash your potential with the transformational power...

Psychedelics

View All Courses

Become 'Brain Healthy'

We're creating a world where every human can be more well through stronger access to critical health data.

Explore the Latest Psychedelic Research

Ketamine use in current clinical practice

… named S- and R-ketamine, with each racemate … -ketamine compared with S(+)-ketamine 2 . Several animal studies have shown that the clearance and volume of distribution of ketamine …

Ketamine

Increased global integration in the brain after psilocybin therapy for depression

… of psilocybin on brain function in two clinical trials of depression. The first was an open-label trial of orally administered psilocybin (10 … controlled trial comparing psilocybin therapy with …

Psilocybin

Rediscovering psilocybin as an antidepressive treatment strategy

… psilocybin over the period of the last 20 years. Despite the promising progress in understanding the mechanisms of psilocybin, … treatment effect sizes for psilocybin as an antidepressant. …

Psilocybin

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

… Pooled analysis of six phase 2 trials of MDMA-assisted therapy for PTSD have … of MDMA-assisted therapy in individuals with severe PTSD. Participants were given three doses of …

MDMA

Browse Psychedelics Data

Need Psychedelics Research Done for Your Organization?

Find Legal Psychedelic Therapy and Experiences

Browse through and connect with thousands of vetted practitioners currently serving people like you.

Use Neuly Care

Participate in a Clinical Trial

Find and enroll in active programs taking place around the world.

Browse Clinical Trials

Stay Informed on Psychedelic Companies

View Public Company Index

Add your Listing to Neuly

Neuly is constantly being updated, and we'd love to add your data!

Get Started

From News to Neuly

Written by Psychedelic Invest • 1 day ago

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that...

DMT

Written by Psilocybin Alpha • 4 days ago

Pα+ Psychedelic Patent Analysis (October 2023)

Written by Psychedelic Alpha’s Noah Smith with support from Editor-at-Large and patent attorney Graham Pechenik of Calyx Law.Our monthly Psychedelic Patent Analysis provides headline figures...

Written by Psychedelics Today • 4 days ago

PT463 – Bringing Intention, Ceremony, and Inner Healing Intelligence to Modern Medicine

In this episode, Joe interviews Dana Lerman, MD: a decade-long infectious disease consultant who has since been trained in psychedelic-assisted therapy, ecotherapy, and Internal Family...

Written by Psychedelic Spotlight • 4 days ago

The Biggest Psychedelic News This Week: November 20th-24th

Psilocybin use shows reduced psychological distress in individuals with adverse childhood experiences, while microdosing shows a "both and" approach to treating ADHD.

Psilocybin

Written by DoubleBlind Mag • 5 days ago

2C-I Unveiled—From Research Chemical to Party Psychedelic

2C-B. DiPT. 4-AcO-DMT. When it comes to the names of novel psychedelic compounds, it sometimes feels like all that’s missing is an “H-I-J-K-L-M-N-O-P.” These new...

LSD

Written by Psychedelics Today • 6 days ago

Explore Kanna: A Legal Psychoactive Plant Ally in Turbulent Times

Dive into the world of Kanna with two prominent leaders in the field of plant medicine, Joe Moore, Founder of Psychedelics Today, and Stephanie Wang,...

Psychedelics